hUC-MSCs and derived exosomes attenuate DEX-induced muscle atrophy through modulation of estrogen signaling pathway.

Na Li, Xiaoqin Liu, Qiong Wang, Yushu Chen, Chao Han, Chao Qu, Xin Guan, Wei Zou, Xiaomin Wang, Ang Li, Yin Zhang, Liping Zhu, Ruoyutong Du, Jing Liu, Yanfu Wang

Department of General Medicine, The First Affiliated Hospital of Dalian Medical University, Dalian, 116011, Liaoning, People's Republic of China. · pubmed

Paper

Abstract

Sarcopenia, a multifactorial syndrome characterized by progressive loss of skeletal muscle mass and strength, combined with impaired physical function, is associated primarily with aging but also driven by chronic inflammation, immobility, and endocrine dysregulation. It leads to increased risks of frailty, falls, and loss of independence, posing a major public health challenge for aging populations. Although human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) and their derived exosomes (MSC-Exos) have demonstrated remarkable potential in regenerative medicine, their safety and efficacy in treating sarcopenia remain unclear. To address this issue, we conducted a preclinical study to systematically evaluate their therapeutic potential and safety.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper claims that hUC-MSCs and their derived exosomes can attenuate muscle atrophy induced by dexamethasone through modulation of the estrogen signaling pathway. This research is relevant as it addresses sarcopenia, a significant age-related condition, and explores potential therapeutic interventions that could mitigate the effects of aging on muscle health.

Author of this paper? Send a correction.